ArticleCurrent oncology reports2006
Targeted molecular therapy of malignant gliomas.
Article in Current oncology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.Journal of neuro-oncology · 2008Guideline
- Targeted therapy in gliomas.Current oncology reports · 2014Review
- Plausible role of naringenin against cerebrally implanted C6 glioma cells in rats.Molecular and cellular biochemistry · 2013Article
- Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats.Neuro-oncology · 2011Article
- Treating brain tumors with PDE4 inhibitors.Trends in pharmacological sciences · 2011Article
- Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.Breast cancer research : BCR · 2011Article
- Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.PloS one · 2010Article
- Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells.British journal of pharmacology · 2010Article
- Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Expert review of neurotherapeutics · 2009Review
- Origins and clinical implications of the brain tumor stem cell hypothesis.Journal of neuro-oncology · 2009Review
- Management of newly diagnosed glioblastoma: guidelines development, value and application.Journal of neuro-oncology · 2009Review
Corrections and comments
- Reprint of
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are the most common form of primary brain tumors in adults. Despite advances in diagnosis and standard therapies such as surgery, radiation, and chemotherapy, the prognosis remains poor. Recent scientific advances have enhanced our understanding of the biology of gliomas and the role of tyrosine kinase receptors and signal transduction pathways in tumor initiation and maintenance, such as the epidermal growth factor receptors, platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and the Ras/Raf/mitogen-activated protein (MAP)-kinase and phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways. Novel targeted drugs such as small molecular inhibitors of these receptors and signaling pathways are showing some activity in initial studies. As we learn more about these drugs and how to optimize their use as single agents and in combination with radiation, chemotherapy, and other targeted molecular agents, they will likely play an increasing role in the management of this devastating disease. This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.